All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition
Ranjana Advani speaks about how CD30 expression levels in patients with T-cell lymphoma (AITL, PTCL-NOS) would affect response to brentuximab vedotin plus cyclophosphamide, doxorubicin, and prednisone.
Dr. Advani explains that the subset analysis was looking at levels of expression of CD30 and whether it correlated with outcomes. For the study entry, 10% or greater expression was required, as determined by immunohistochemistry (ICH).
ECHELON-2 trial: response by CD30 expression
Brentuximab vedotin plus chemotherapy for CD30+ PTCL: Results from the phase III ECHELON-2 trial
ECHELON-2 is a global, double-blind, active-comparator, randomized, phase III trial that investigated the efficacy and safety of brentuximab vedotin plus...
FDA grants Breakthrough Therapy Designation to brentuximab vedotin (Adcetris®) for frontline PTCL
In November 2018, the FDA granted Breakthrough Therapy Designation to brentuximab vedotin for use in front-line PTCL
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox